Milestone
Molecular Partners AG, which is pioneering the development of DARPins, a novel class of therapeutic proteins, has announced that it has reached all milestones of the research phase of its collaboration with Centorcor earlier than anticipated, successfully selecting and characterising DARPin antagonists to multiple targets.
The collaboration began in January 2008. “We are very pleased with the rapid progress of this collaboration”, said Christian Zahnd, CEO of Molecular Partners. “This is a significant step forward in our strategy to strengthen our proprietary pipeline with selected partnered compounds.”
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.